Conditions: Primary Fibromyalgia
Keywords: Fibromyalgia Pediatric Fibromyalgia Adolescent Fibromyalgia milnacipran Savella loss of therapeutic response Forest Research Institute Pain Fatigue Serotonin Norepinephrine Reuptake Inhibitors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 57
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.

Detailed description:

Arms:
arm 1: oral administration, twice daily dosing

Interventions: intervention 1: Milnacipran
Intervention descriptions: intervention 1: maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.

Protocol document: